Atherogenesis is a chronic inflammatory process. Critical in the inflammation process is monocyte chemoattractant protein-1 (MCP-1). To locate genomic regions that affect circulating MCP-1 levels, a genome-wide linkage scan was conducted in a sample of whites and blacks. Phenotype and genetic marker data were available for 2501 white and 513 black participants in the National Heart Lung Blood Institute Family Heart Study follow-up examination. Heritability for MCP-1 was 0.37 in whites and 0.47 in blacks after adjusting for the effects of sex, age, age-sex interaction, smoking status, lifetime smoking exposure (pack-years) and field center. Significant linkage was observed for MCP-1 in a combined black and white sample on chromosome 3 (logarithm of the odds ratio (LOD) ¼ 3.5 at 78 cM, P ¼ 0.0001) and suggestive linkage was observed in whites on chromosome 5 (LOD ¼ 1.8 at 128 cM, P ¼ 0.002). Located under the linkage peak on chromosome 3 is the chemokine receptor gene cluster, including CCR2, the receptor for MCP-1. This study provides preliminary evidence linking genetic variation in a receptor to circulating levels of its ligand, as previously demonstrated for the low-density lipoprotein receptor. Further characterization of these chromosomal regions is needed to identify the functional mutations associated with circulating levels of MCP-1.
Introduction
Atherogenesis is a chronic inflammatory process. The steps in the inflammatory process include accumulation of lipids, recruitment of leukocytes and smooth muscle into vessel walls and accumulation of extracellular matrix. Chemoattractants such as monocyte chemoattractant protein-1 (MCP-1) are critical for leukocyte migration and activation and therefore may play a role in the development of atherosclerosis. Atherosclerosisprone mice deficient in MCP-1 (MCP1 À/À ) or its receptor CCR2 (CCR2 À/À ) have smaller and decreased numbers of lesions compared to wild-type mice. 1, 2 Evidence for a role for MCP-1 in atherogenesis has also been reported in human tissue. MCP-1 expression was upregulated in human atheromatous plaques compared to normal tissue 3 and in endothelial and smooth muscle cells exposed to modified low-density lipoprotein (LDL). 4 In human studies, serum levels of MCP-1 have been associated with older age, female sex, hypertension, diabetes, history of coronary disease, renal insufficiency, measures of adiposity and other inflammatory mediators including C-reactive protein (CRP), interleukin-6, interleukin-18, interleukin-8 and IP-10. [5] [6] [7] However, the relationship between levels of MCP-1 and risk of atherosclerotic diseases is inconsistent. Researchers using the Framingham Heart Study cohort reported that allele À2578G in the MCP-1 gene was significantly associated with increased serum levels of MCP-1 and a higher prevalence of myocardial infarction (MI). 8 In the Atherosclerosis Risk in Communities Study, mean plasma MCP-1 levels were found to be significantly higher in peripheral arterial disease 9 and in the Shimanami Health Promoting Program serum MCP-1 was associated with carotid intima-medial thickness. 10 In contrast to these findings, levels of MCP-1 were not associated in other human study populations with stable coronary heart disease, 11 presence of atherosclerosis or previous MI 12 or incident MI 13 in multivariable models. In some studies, serum MCP-1 levels are not an independent risk factor for cardiovascular disease as adjustment for established risk factors attenuates associations with disease outcomes. 6, 13 However, MCP-1's role in the underlying physiological mechanisms of atherosclerosis warrants further study. Genetic factors may partly account for interindividual variation in MCP-1. Heritabilities ranging from 0.34 to 0.50 have been reported.
14 Therefore, we conducted a genome-wide linkage scan for quantitative trait loci influencing circulating MCP-1 levels. The identification of genes contributing to variation in this inflammation biomarker may point to etiological pathways that further clarify the role of MCP-1 in atherogenesis.
Results
Genetic and phenotypic data were available on 2501 white subjects in 482 pedigrees and 513 black subjects in 158 pedigrees. Characteristics of pedigrees used in the linkage scan are shown in Table 1 . Significant differences in mean MCP-1 levels were observed for age, sex, ageÃsex interaction, race, diabetes status and adiposity for both blacks and whites using mixed effect models as implemented in Sequential Oligogenic Linkage Analysis Routines (SOLAR) to account for the lack of independence due to familial aggregation. Additionally, smoking status, lifetime exposure to smoking and field center were significant in whites only. Baseline characteristics of the study population and a race-specific comparison of mean levels of MCP-1 by several characteristics are shown in Table 2 . Subjects ranged in age from 32 to 93 years, with a mean age of 57 in whites and 53 in blacks, and over half were women. In both blacks and whites, diabetics had higher levels of MCP-1 than non-diabetics, and levels increased with age. Mean MCP-1 levels were higher in smokers vs non-smokers with evidence of a dose-response relationship with higher levels observed across the quintiles of smoking exposure. Adiposity was positively associated with MCP-1 levels and a doseresponse relationship was observed for waist circumference and body mass index with higher mean levels across body mass index categories and quintiles of waist circumference.
Adjusted heritability was 0.37 and 0.47 for whites and blacks, respectively (Table 3) . Heritability estimates were stable with or without adjustment for covariates. Under the null model, 10 000 logarithm of the odds ratio (LOD) scores were simulated for MCP-1 (range 0-2.97) and used to estimate empirical P-values. Race-specific multipoint LOD scores are plotted by map position for each chromosome in Figure 1 . A significant LOD score was observed for MCP-1 in a combined black and Abbreviations: BMI, body mass index; MCP-1, monocyte chemoattractant protein-1; NHLBI FHS, National Heart Lung Blood Institute Family Heart Study.
MCP-1 shows linkage to chemokine receptor cluster SJ Bielinski et al white sample on chromosome 3 (LOD ¼ 3.5 at 78 cM, P ¼ 0.0001) ( Figure 2 ) and a suggestive LOD score was observed on chromosome 5 in whites (LOD ¼ 1.8 at 128 cM, P ¼ 0.002).
Discussion
Identifying genetic factors affecting MCP-1 levels may aid in our understanding of the underlying biological mechanisms responsible for cardiovascular disease and MCP-1 shows linkage to chemokine receptor cluster SJ Bielinski et al related risk factors. To that end, we conducted genomewide linkage analysis to identify genomic regions for further characterization. We found moderate heritabilities ranging from 0.37 to 0.47, suggesting a genetic component influencing plasma levels. These estimates are consistent with the previously published report in the Framingham Heart Study. 14 Significant evidence for linkage for MCP-1 was observed in a combined sample of blacks and whites on chromosome 3 (LOD ¼ 3.5 at 78 cM, P ¼ 0.0001). Evidence for linkage was present in both blacks (LOD ¼ 1.1 at 72 cM) and whites (LOD ¼ 2.7 at 78 cM). This result appears to be a novel finding as the only other published linkage scan for MCP-1 found little evidence for linkage on this chromosome (LODo0.5).
14 However, this region on chromosome 3 contains the chemokine receptor gene cluster, including CCR2, the receptor for MCP-1 located at approximately 70 cM. CCR2-mediated recruitment of monocytes is critical in the process of atherosclerosis. 15 This study provides preliminary evidence linking genetic variation in a receptor to circulating levels of its ligand, as previously demonstrated for the LDL receptor. 16, 17 CCR2 expression was significantly correlated with plasma LDL and inversely with high-density lipoprotein and expression was increased 2.4-fold in monocytes from hypercholesterolemic patients compared to controls. Furthermore, estrogen therapy reduced CCR2 expression in hypercholesterolemic postmenopausal women compared to normocholesterolemic women. This suggests that plasma lipoproteins affect monocyte functions and hypercholesterolemia enhances chemotaxis by MCP-1.
15
In contrast with native LDL, modified LDL is a negativeregulator of CCR2 expression and has been shown to cause rapid loss of functional CCR2 protein, and inhibits the physiological response of monocytes to MCP-1. Inhibition was more pronounced with extensively modified LDL in a dose-dependent manner and is hypothesized to block reverse transmigration and accelerating atherosclerosis by causing monocytes to remain in the intima allowing for maturation into macrophages. 18 The CCR2 gene is located at 3p21.31 and contains three exons. This gene is not well annotated and none of the six single-nucleotide polymorphisms and one deletion/ insertion listed in the National Center for Biotechnology Information database has been genotyped in HapMap. Three of the single-nucleotide polymorphisms are nonsynonymous (rs4987052, rs1799864 and rs3918387) and may be of functional importance. One common variant in CCR2, Val64Ile (rs1799864), has been associated with coronary artery calcium with the rarer 64Ile allele associated with decreased coronary artery calcium independent of sex and other traditional risk factors. 19 This allele has also been associated with early-onset MI 20, 21 and heart failure but not coronary atherosclerosis suggesting a less stable plaque morphology due to lack of calcification that may explain increased risk of MI observed in carriers of 64Ile. 20 However, the Val64Ile allele was not associated with MI in a retrospective study of patients in Iceland who survived an MI at 37-69 years of age. 22 Two isoforms of the receptor, CCR2A and CCR2B, are the result of alternative splicing. Using Jurkat T cells transfected with plasmids encoding the human CCR2A or CCR2B gene, Sanders et al. 23 observed that MCP-1 bound to both forms with high affinity but a fivefold less MCP-1-induced chemotaxis was noted in CCR2B-expressing cells compared to CCR2A-expressing cells. Genetic variation that affects splicing and consequently circulating MCP-1 may be contributing to the linkage signal in this region. Further characterization of this region is required to determine the effect of CCR2 polymorphisms on circulating levels of MCP-1. Other related genes are located under the linkage peak and include chemokine receptors 1-9 and the chemokine decoy receptor D6.
A linkage peak was also observed on chromosome 5 in whites (LOD ¼ 1.8 at 128 cM, P ¼ 0.002). Chromosome 5 is one of the largest of the human chromosomes yet has one of the lowest gene densities. 24 A search of the National Center for Biotechnology Information database under the linkage peak region did not reveal any genes that are known to affect MCP-1. However, Schmutz et al. 24 analyzed chromosome 5 and observed a high density of conserved non-coding elements in gene poor regions concluding that these regions contain elements that regulate distant genes. Although this region did not meet genome-wide significance, fine mapping of this area is required to exclude this region as influential to MCP-1 levels or to pinpoint a possible gene or regulatory element responsible for the linkage signal.
The major weakness of this study is that linkage analysis is a hypothesis-generating methodology that is sensitive to complexities in population structure, etiological heterogeneity and complex gene-gene and geneenvironment interactions. It is possible that there is genetic heterogeneity within the cohort that may mask the linkage signals. In addition, the cohort is culturally and geographically dispersed and gene-environment interactions may differ across subgroups. The degree to which these factors impact the linkage results is unknown. In addition, power was limited due to the small sample size of black pedigrees.
Conclusion
This investigation into the genetics of MCP-1 levels revealed heritabilities ranging from 0.37 to 0.47 in a sample of white and black subjects. Linkage was observed in a combined sample of whites and blacks on chromosome 3 near the chemokine receptor gene cluster and on chromosome 5. The chemokine receptor gene cluster includes the receptor for MCP-1, CCR2. This study provides preliminary evidence linking genetic variation in a receptor to circulating levels of its ligand, as previously demonstrated for the LDL receptor. Further characterization of these chromosomal regions is needed to identify the functional mutations associated with circulating levels of MCP-1.
Methods

Subjects
In its follow-up examination, the National Heart Lung Blood Institute (NHLBI) Family Heart Study (FHS) enrolled previously examined and genotyped participants from the original NHLBI FHS and Hypertension Epidemiology Network along with a newly recruited group consisting primarily of black families. 25, 26 NHLBI FHS originally recruited three-generation pedigrees from three population-based studies with approximately half the pedigrees randomly selected and the other half selected on the basis of having higher than expected rates of coronary heart disease. Hypertension Epidemiology Network recruited hypertensive siblings and a random sample of the population. In addition, relatives of participants in FHS and Hypertension Epidemiology Network were enrolled. This follow-up examination included 3359 participants, including 622 African Americans. The study protocol was approved and monitored by the Institutional Review Board at each clinic site. Participants completed a consent process that included detailed descriptions of research goals, examination procedures, DNA use and research subject rights.
Measurements
Participants were asked to change into a scrub suit or examination gown and were given the opportunity to empty their bladder prior to anthropometric measurements. Hip and waist circumferences were measured at the maximal protrusion of the hips and at the level of the umbilicus, respectively, with the participant standing erect. Height was measured while participants were standing without shoes, heels together against a vertical mounted ruler. A Detecto Platform Balance Scale was used to measure weight. Body mass index was calculated as weight (kg) per height 2 (m 2 ). Medical and personal histories were ascertained via interview and participants self-reported diabetes, hypertension and hypercholesterolemia. Smoking exposure was assessed by current smoking status and lifetime exposure (pack-years). Participants were asked to bring all prescription medications taken in the previous 4 weeks and an interviewer transcribed this information. MCP-1 was measured from frozen citrated plasma specimens using an ultrasensitive ELISA assay (Quantikine Human MCP-1 Immunoassay; R&D Systems, Minneapolis, MN, USA). This assay employs the quantitative sandwich enzyme immunoassay technique and samples were run in duplicate in order they were received by the laboratory.
Genotyping
Genotypes for microsatellite markers throughout the genome were provided by the NHLBI Mammalian Genotyping Service and the University of Texas Health Science Center at Houston. The markers were from Cooperative Human Linkage Center (CHLC) screening set 10 (408 markers) spaced at approximately 10 cM intervals. Primers tagged by fluorescent dyes were used to amplify microsatellite markers for electrophoresis to distinguish alleles that differ by numbers of short repeats. Quality control measures included checking genotypes for consistency with pedigree relationships, as well as inclusion of samples with known genotypes (CEPH) to ensure accurate and consistent allele designations.
Statistical methods
Heritability and covariate effects were estimated and genome scans were performed using the variance components approach as implemented in SOLAR. 27 This method is an implementation of the Amos method that uses extended pedigree data rather than restricting the linkage analysis to sibships. 28 Variance component methods model phenotypic covariances between relatives as a function of the identity-by-descent (IBD) relationships of alleles a given locus and other factors. 29 Two alleles are said to show IBD when they are both copies of the same ancestral allele. IBD relations are estimated using genetic marker data. The variance component model tests the null hypothesis that there is no linkage (that is the additive genetic variance due to the quantitative trait loci is zero) by comparing the likelihood of the restricted (null) model to a model in which the variance of the quantitative trait loci is estimated. 30 Conceptually, linkage analysis identifies excess allele sharing among relatives at a locus linked to a gene that influences concordant phenotypic levels among relatives.
The IBD probabilities for the small families were computed by MERLIN. MERLIN uses the Lander-Green algorithm to estimate the probability that any two individuals actually inherited the same allele from founders in the pedigree. 31 For the seven largest families, Loki was used to compute IBD probabilities. Loki uses Markov chain Monte Carlo techniques to estimate the IBD relationship matrices for large and complex pedigrees while avoiding the computational issues that prevent the use of the precise Lander-Green algorithm. 32, 33 The MERLIN and Loki IBD files were converted into SOLAR format using the program MER2SOL for use in linkage analysis. 34 The SOLAR lodadj procedure was used to simulate the expected distribution of LOD scores for a given phenotype under the null model. This procedure has been described in detail elsewhere. 30, 35 Briefly, this procedure simulates a fully informative marker completely unlinked to the trait and tests the trait linkage at that marker to determine the LOD score distribution under the null model. Empirical P-values were estimated as (r þ 1)/(n þ 1), where n is the number of replicate samples simulated and r is the number of those replicates with LOD exceeding or equaling the observed LOD. 36 MCP-1 levels were logarithmically transformed to normalize the distribution. The distribution was truncated to reduce kurtosis by excluding participants with log transformed levels 74 standard deviations from the mean (n ¼ 12). The resulting kurtosis for all the samples was 1.1-2.6 for MCP-1. The 'tdist' option in SOLAR, which is robust to high kurtosis values, was used for the genome scan. 30 In SOLAR, MCP-1 was adjusted for the effects of sex, age, ageÃsex interaction, smoking status, lifetime smoking exposure (pack-years) and field center.
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